Showing 2 posts of 2 posts found.
Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo (SPT-300), an oral prodrug of …
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Santen joins inaugural Global Summit for Eye Health as partner
EHP Awards 2027 open for entries following outstanding inaugural year
NHS spends £240m storing patient records as digital reforms gather pace
NHS awards national diabetes education contract to Leicester programme
InnoScot highlights NHS Scotland’s progress towards net zero healthcare